The NHS in England will introduce a new weight loss drug, Mounjaro, next year, but only 6.5% of eligible patients will have access due to limited resources. The drug is recommended for patients with obesity and related health conditions, but its rollout will take years, and many will have to wait. The decision reflects ongoing debates in Europe about funding anti-obesity treatments and their long-term effectiveness. Teljes cikk (Euronews.com)